ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model

Scandinavian Journal of Immunology

Volumn 78, Issue 1, 2013, Pages 69-78

  He, X ^a,b   Wang, J ^a   Zhao, F ^a   Chen, D ^a   Chen, J ^a   Zhang, H ^a   Yang, C ^a   Liu, Y ^a   Dou, J ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; EARLY SECRETED ANTIGENIC TARGET DNA VACCINE; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL; INTERLEUKIN 21; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CELL MATURATION; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYSIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR CELL;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CANCER VACCINES; CELL LINE, TUMOR; GLYCOSYLPHOSPHATIDYLINOSITOLS; IMMUNIZATION; INTERLEUKINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VACCINES, DNA;

EID: 84880292229     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12074     Document Type: Article

References (37)

1. Ilkovitch D, Diana ML. Immune modulation by melanoma-derived factors. Exp Dermatol 2008;17:977-85.
2. Schadendorf D, Paschen A, Sun Y. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol Lett 2000;74:67-74.
3. Alexander MM, Eggermont DS. Melanoma and immunotherapy. Hematol Oncol Clin North Am 2009;23:547-64.
4. Zhao FS, Dou J, Wang J et al. Investigation on the anti-tumor efficacy by expression of GPI- anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice. Immunobiology 2010;215:89-100.
5. Polak ME, Borthwick NJ, Jager MJ, Cree IA. Melanoma vaccines: the problems of local immunosuppression. Hum Immunol 2009;70:331-9.
6. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006;12:2353s-8s.
7. Restifo NP. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000;12:597-603.
8. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-34.
9. Smahel M, Poláková I, Pokorná D. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Int J Oncol 2008;33:93-101.
10. Weihua H, Jing W, Jun D et al. Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplatat 2011;20:669-80.
11. Dou J, Chu LL, Zhao FS et al. Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in Balb/c mice. Cancer Biol Ther 2007;6:1871-9.
12. Ganguly N, Giang PH, Basu SK. Mycobacterium tuberculosis 6-kDa early secreted antigenic target (ESAT-6) protein downregulates lipopolysaccharide induced c-myc expression by modulating the extracellular signal regulated kinases 1/2. BMC Immunol 2007;8:24.
13. Dou J, Wang YQ, Yu FL et al. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet 2012;39:183-90.
14. Smyth MJ, Teng MW, Sharkey J. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 2008;68:3019-25.
15. Ji JF, Li JH, Lillia MH. Synergistic anti-tumor effect of glycosylpho-sphatidylinositol-anchored IL-2 and IL-12. J Gene Med 2004;6:777-85.
16. Butikofer P, Malherbe T, Boschung M. GPI-anchored proteins: now you see 'em, now you don't'. FASEB J 2001;15:545-8.
17. Zhao FS, Dou J, He XF et al. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine 2010;28:2846-52.
18. Dou J, Liu P, Wang J. Cellular response to gene expression profiles of different hepatitis C virus core protein in Huh-7 cell line with microarray analysis. J Nanosci Nanotechnol 2005;5:209-14.
19. Dou J, Tang Q, Yu FL et al. Investigation of immune effect based on BCG priming and Plasmid DNA expressing Ag85A & GM-CSF boosting in Balb/c mice model. Immunobiology 2010;215:133-42.
20. Hyesung K, Hyemi P, Jungsun P. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine 2010;28:7787-96.
21. Groh V, Steinle A, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279:1737-40.
22. Dou J, Wang YF, Wang J et al. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model. Immunobiology 2009;214:483-92.
23. He XF, Wang J, Zhao FS et al. Anti-tumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse. Immunol Res 2012;52:240-9.
24. Naeem K, Donna B, Rachel B. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 2007;178:4455-65.
25. + T cells in patients with melanoma. J Immunol 2005;175:6169-76.
26. Dou J, Wu Y, Wang J et al. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Cancer Gene Ther 2010;17:675-83.
27. Atanackovic D, Panse J, Hildebrandt Y. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologic 2011;96:512-20.
28. Matsui W, Huff CA, Wang Q. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-6.
29. Dou J, Pan M, Wen P et al. Isolation and identification of cancer stem like cells from murine melanoma cell lines. Cell Mol Immunol 2007;4:528-33.
30. Hervé L, Michèle F, Sylvie G. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 2001;253:177-87.
31. Ni J, Schirrmacher V, Fournier P. The hemagglutinin-neuraminidase gene of newcastle disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. Vaccine 2010;28:6891-900.
32. Tseng CW, Monie A, Trimble C. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008;26:4314-19.
33. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J 2010;6:392-8.
34. Millington KA, Fortune SM, Low J. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 2011;108:5730-5.
35. Olsen AW, Hansen PR, Holm A. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 2000;30:1724-32.
36. K, Shin E, Ayumi Y. targeting apoptotic tumor cells to fcγr provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 2003;170:1641-8.
37. Capitini CM, Fry TJ, Mackall CL. Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am J Immunol 2009;5:65-83.